glp 1 off label use A clinician's perspective 📝 GLP-1 receptor agonists are primarily approved for type 2 diabetes, weight management, and cardiovascular risk reduction, but are increasingly used off-label in dermatology where metabolic dysfunction plays a GLP -1 and GIP Off-Label

COTI-2 has been shown to suppress tumor growth by inducing apoptosis and cell cycle arrest in both p53-dependent and p53-independent manners

With the recent FDA approval of an oral Wegovy pill marking an important shift in the GLP-1 landscape, Dr

Initiation and progression of PD is dependent upon cellular events, including failures in the protein degradation machinery, oxidative stress, mitochondrial dysfunction, defects in mitochondrial autophagy (mitophagy) and the continuous accumulation of -synuclein, driven through cell to cell interactions between glial cells and neurons that ultimately lead to apoptosis [7,10,18]

January 2025

Each receptor contributes a different piece: GLP-1 reduces appetite and slows digestion GIP improves insulin sensitivity and fat metabolism Glucagon increases energy expenditure and fat breakdown The result is up to 24% average weight loss in Phase 2 trials, with Phase 3 data showing even higher numbers (28.7% at 68 weeks)